Christopher P Guise
Overview
Explore the profile of Christopher P Guise including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
644
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashoorzadeh A, Mowday A, Abbattista M, Guise C, Bull M, Silva S, et al.
ACS Med Chem Lett
. 2023 Nov;
14(11):1517-1523.
PMID: 37974941
Off-target aerobic activation of PR-104A by human aldo-keto reductase 1C3 (AKR1C3) has confounded the development of this dual hypoxia/gene therapy prodrug. Previous attempts to design prodrugs resistant to AKR1C3 activation...
2.
Ashoorzadeh A, Mowday A, Guise C, Silva S, Bull M, Abbattista M, et al.
Pharmaceuticals (Basel)
. 2022 Feb;
15(2).
PMID: 35215297
PR-104A is a dual hypoxia/nitroreductase gene therapy prodrug by virtue of its ability to undergo either one- or two-electron reduction to its cytotoxic species. It has been evaluated extensively in...
3.
Abbattista M, Ashoorzadeh A, Guise C, Mowday A, Mittra R, Silva S, et al.
Pharmaceuticals (Basel)
. 2021 Dec;
14(12).
PMID: 34959631
PR-104 is a phosphate ester pre-prodrug that is converted in vivo to its cognate alcohol, PR-104A, a latent alkylator which forms potent cytotoxins upon bioreduction. Hypoxia selectivity results from one-electron...
4.
van der Wiel A, Jackson-Patel V, Niemans R, Yaromina A, Liu E, Marcus D, et al.
Mol Cancer Ther
. 2021 Oct;
20(12):2372-2383.
PMID: 34625504
Hypoxia-activated prodrugs (HAP) are a promising class of antineoplastic agents that can selectively eliminate hypoxic tumor cells. This study evaluates the hypoxia-selectivity and antitumor activity of CP-506, a DNA alkylating...
5.
Mowday A, Dubois L, Kubiak A, Chan-Hyams J, Guise C, Ashoorzadeh A, et al.
Cancer Gene Ther
. 2021 Feb;
29(2):178-188.
PMID: 33558701
Necrosis is a typical histological feature of solid tumours that provides a selective environment for growth of the non-pathogenic anaerobic bacterium Clostridium sporogenes. Modest anti-tumour activity as a single agent...
6.
Williams E, Rich M, Mowday A, Ashoorzadeh A, Copp J, Guise C, et al.
Biochemistry
. 2019 Aug;
58(35):3700-3710.
PMID: 31403283
Gene-directed enzyme prodrug therapy (GDEPT) uses tumor-tropic vectors to deliver prodrug-converting enzymes such as nitroreductases specifically to the tumor environment. The nitroreductase NfsB from (NfsB_Ec) has been a particular focal...
7.
Sansom G, Kirk N, Guise C, Anderson R, Smaill J, Patterson A, et al.
Bioorg Med Chem Lett
. 2019 Mar;
29(10):1215-1219.
PMID: 30885680
Amide- and ester-linked kinase inhibitor-cytotoxin conjugates were rationally designed and synthesised as prototype hypoxia-activated anticancer mutual prodrugs. Chemical reduction of an aryl nitro trigger moiety was shown to initiate a...
8.
Spiegelberg L, Houben R, Niemans R, De Ruysscher D, Yaromina A, Theys J, et al.
Clin Transl Radiat Oncol
. 2019 Feb;
15:62-69.
PMID: 30734002
Hypoxia-activated prodrugs (HAPs) are designed to specifically target the hypoxic cells of tumors, which are an important cause of treatment resistance to conventional therapies. Despite promising preclinical and clinical phase...
9.
Mo C, Zhang Z, Guise C, Li X, Luo J, Tu Z, et al.
ACS Med Chem Lett
. 2017 May;
8(5):543-548.
PMID: 28523108
A series of 2-aminopyrimidine derivatives were designed and synthesized as highly selective FGFR4 inhibitors. One of the most promising compounds tightly bound FGFR4 with a value of 3.3 nM and...
10.
Li X, Guise C, Taghipouran R, Yosaatmadja Y, Ashoorzadeh A, Paik W, et al.
Eur J Med Chem
. 2017 May;
135:531-543.
PMID: 28521156
A series of 2-oxo-3, 4-dihydropyrimido[4,5-d]-pyrimidinyl derivatives were designed and synthesized as new irreversible inhibitors of the FGFR family. One of the most promising compounds 2l potently inhibited FGFR1/2/3 with IC...